Pancreatic cancer: open trials in Denmark

• NCT07563738

  A 2-part Phase 1/2 Open-label Trial on ODM-212

  Trial Treatment · Phase 1/2 · Orion Corporation, Orion Pharma

  Aalborg Universitets hospital, Aalborg · Rigshospitalet University, Copenhagen

  Registry updated 2026-11-05

• NCT06760819

  A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  Trial Treatment · Phase 2 · Bayer

  Aarhus University Hospital | Oncology Department - Clinical Research Unit, Aarhus N · Rigshospitalet Copenhagen University Hospital | Oncology Department, Copenhagen · Odense University Hospital | Svendborg Sygehus - Oncology Department, Odense

  Registry updated 2026-11-04

• NCT04924075

  Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

  Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC

  Rigshospitalet (Site 0304), Copenhagen · Rigshospitalet-Department of Endocrinology (Site 0303), Copenhagen · Odense Universitetshospital (Site 0302), Odense C

  Registry updated 2026-11-03

• NCT07522073

  A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

  Trial Treatment · Phase 3 · Incyte Corporation

  Aalborg · Århus N · Herlev · Køge · Odense C · Vejle

  Registry updated 2026-10-30

• NCT06914128

  A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  Trial Treatment · Phase 1/2 · Bayer

  Rigshospitalet Copenhagen University Hospital | Oncology Department, Copenhagen · Odense University Hospital | Svendborg Sygehus - Oncology Department, Odense

  Registry updated 2026-10-28

• NCT07261631

  Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

  Trial Treatment · Phase 1 · Novartis Pharmaceuticals

  Odense C

  Registry updated 2026-10-09

• NCT07491445

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  Trial Treatment · Phase 3 · Revolution Medicines, Inc.

  Region Midtjylland, Aarhus N · Region Hovedstaden, Herlev · Odense University Hospital, Odense C

  Registry updated 2026-10-02

• 2025-524160-38-00

  A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Region Hovedstaden, Herlev

  Registry updated 2026-10-01

• 2025-524928-21-00

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  Trial Treatment · Phase 3 · Revolution Medicines Inc.

  Region Hovedstaden, Herlev

  Registry updated 2026-09-25

• 2025-525009-18-00

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  Trial Treatment · Phase 3 · Incyte Corp.

  Aalborg University Hospital, Aalborg · Region Midtjylland, Aarhus N · Region Hovedstaden, Herlev · Odense University Hospital, Odense C · Region Sjaelland, Roskilde · Lillebaelt Hospital, Vejle

  Registry updated 2026-09-25

• NCT05663515

  A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

  Research · AstraZeneca

  Copenhagen

  Registry updated 2026-09-24

• 2024-519667-18-00

  Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial

  Trial Treatment · Phase 4 · Amsterdam UMC Stichting

  Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe

  Registry updated 2026-09-17

• NCT07821554

  Personalised Nutritional Care in Older Patients With Pancreatic Ductal Adenocarcinoma

  Trial Treatment · Inna Chen, MD

  Department of Oncology, Herlev

  Registry updated 2026-09-16

• 2025-521702-18-00

  A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors

  Trial Treatment · Phase 1 · Novartis Pharma AG

  Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C

  Registry updated 2026-09-15

• 2024-513900-32-00

  Master protocol of TCR-modified T cell therapy targeting HLA-restricted KRAS antigen administered in adult patients with metastatic or locally advanced PDAC

  Trial Treatment · Phase 1/2 · Anocca AB

  Region Hovedstaden, Herlev

  Registry updated 2026-09-10

• NCT06713525

  Observational Copenhagen Pancreatic Cancer Study

  Research · Inna Chen, MD

  Department of Oncology, Herlev

  Registry updated 2026-09-04

• NCT07802418

  Molecularly Tailored Therapy in Advanced Pancreatic Cancer

  Trial Treatment · Phase 2 · Herlev Hospital

  Department of Oncology, Aalborg · Department of Oncology, Aarhus · Department of Oncology, Herlev · Department of Oncology, Vejle

  Registry updated 2026-09-03

• NCT04611867

  Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)

  Trial Treatment · Inna Chen, MD

  Herlev & Gentofte University Hospital, Denmark, Herlev

  Registry updated 2026-09-02

• NCT07630961

  Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

  Trial Treatment · Phase 1 · Novartis Pharmaceuticals

  Odense C

  Registry updated 2026-08-27

• NCT07094113

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  Trial Treatment · Phase 1 · Amgen

  Rigshospitalet, Copenhagen

  Registry updated 2026-07-30

• 2025-523665-24-00

  A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors

  Trial Treatment · Phase 1 · Novartis Pharma AG

  Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C

  Registry updated 2026-06-10

• NCT07629609

  BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

  Trial Treatment · Phase 2 · Barbara Malene Fischer

  Rigshospitalet, Copenhagen Oe

  Registry updated 2026-06-05

• NCT07201194

  Holistic Acupuncture for Patients With Chemotherapy Induced Nausea

  Trial Treatment · Vejle Hospital

  Department of Oncology, Vejle Hospital, Vejle

  Registry updated 2026-05-28

• 2025-522431-34-00

  Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer

  Trial Treatment · Phase 2 · Region Hovedstaden

  Aalborg University Hospital, Aalborg · Region Midtjylland, Aarhus N · Region Hovedstaden, Herlev · Sygehus Lillebaelt - Vejle Sygehus, Vejle

  Registry updated 2026-05-18

• NCT05428358

  Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

  Trial Treatment · University of Aarhus

  Aalborg University Hospital, Aalborg · Aarhus University Hospital, Aarhus · Rigshospitalet, Copenhagen

  Registry updated 2026-04-29

All Pancreatic cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error